Name of journal: *World Journal of Diabetes*

ESPS Manuscript NO: 11656

Columns: Editorial

**Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance**

Desai GS *et al.* Saliva as a diagnostic tool

Gauri S Desai, Suresh T Mathews

**Gauri S Desai, Suresh T Mathews,** Department of Nutrition and Dietetics, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, AL 36849, Auburn, United States

**Author contributions:** Desai GS and Mathews ST contributed equally to this work.

**Supported by** Auburn University Intramural Grants Program

**Correspondence to:** Suresh T Mathews, PhD,Associate Professor and Graduate Program Director,Department of Nutrition and Dietetics, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University,260 Lem Morrison Dr., 101 PSB,Auburn, AL 36849, United States.mathest@auburn.edu

**Telephone:** +1-334-8447418 **Fax:** +1-334-8443268

**Received:** May 29, 2014 **Revised:** October 20, 2014

**Accepted:** October 31, 2014

**Published online:**

**Abstract**

Saliva has been progressively studied as a non-invasive and relatively stress-free diagnostic alternative to blood. Currently, saliva testing is used for clinical assessment of hormonal perturbations, detection of HIV antibodies, DNA analysis, alcohol screening, and drug testing. Recently, there has been increasing interest in evaluating the diagnostic potential of saliva in obesity, inflammation, and insulin-resistance. Current literature has demonstrated elevated levels of inflammatory biomarkers including C-reactive protein, tumor necrosis factor-α, interleukin-6, and interferon-γ in saliva of obese/overweight children and adults. Salivary antioxidant status has also been studied as a measure of oxidative stress in individuals with type 2 diabetes. Further, several studies have demonstrated correlations of salivary markers of stress and insulin resistance including cortisol, insulin, adiponectin, and resistin with serum concentrations. These findings suggest the potential diagnostic value of saliva in health screening and risk stratification studies, particularly in the pediatric population, with implications for inflammatory, metabolic and cardiovascular conditions. However, additional studies are required to standardize saliva collection and storage procedures, validate analytical techniques for biomarker detection, and establish reference ranges for routine clinical use. The purpose of this review is to summarize and evaluate recent advancements in using saliva as a diagnostic tool for inflammation and insulin-resistance.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Saliva; Inflammation; Cytokines; Insulin resistance; Adipokines

**Core tip:** Recent studies have shown that salivary concentrations of several inflammatory cytokines and insulin resistance indices (which may be lower than serum concentrations) may mirror alterations in systemic concentrations of such biomarkers. Saliva offers a promising diagnostic alternative, compared to blood sampling, for screening for inflammatory, metabolic, and cardiovascular risk factors particularly among pediatric and geriatric populations where blood sampling may be difficult. Additional research is needed to validate salivary biomarkers and establish reference ranges and characterize the influence of diet, physical activity, and drug treatment.

Desai GS, Mathews ST. Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance. *World J Diabetes* 2014; In press

**SALIVA AS A DIAGNOSTIC TOOL: CURRENT KNOWLEDGE**

Saliva, an exocrine secretion of the salivary glands, containing water (99%), electrolytes, proteins, and enzymes, provides sensory perception of food, and aids chewing, swallowing, and digestion of food[1]. Saliva protects tissues against desiccation, penetration, ulceration, potential carcinogens, and assists in wound healing[2]. Whole saliva comprises of a mixture of fluids, secreted from the salivary glands (submandibular, sublingual, and parotid, and the minor gland), gingival fold, oral mucosa transudate, and, mucous from the nasal cavity and pharynx, that vary in rheological properties and the composition of their secretions[3-6]. The parotid gland secretions are largely composed of water and electrolytes, while the submandibular and sublingual glands produce both serous and mucous secretions, with mucin being the most abundant protein in saliva[7]. Saliva also contains cystatins, proline-rich peptides (PRPs), and other molecules that are found in blood[4,8]. Saliva is hypotonic to plasma and is actively involved in exchange of sodium (Na+), chloride (Cl-), potassium (K+) and bicarbonate (HCO3-) ions with plasma[7]. Proteins and other substances from blood have been shown to enter saliva intracellularly through passive diffusion or active transport, and paracellularly through ultrafiltration at tight junctions between cells[9]. Saliva can be collected by passive drool technique or by using oral swabs. In healthy individuals, depending on age and gender, the unstimulated salivary flow rate is between 0.1-2 mL/min[10]. Additional factors influencing unstimulated salivary flow and composition include individual hydration, body posture, lighting, smoking, circadian and circannual rhythms, and medications[1].

The use of saliva as an alternative diagnostic tool to blood offers certain advantages. Salivary composition has been observed to be influenced by systemic changes allowing identification of biomarkers for disease conditions. Since saliva collection is non-invasive and relatively stress-free, saliva can serve as a potential alternative diagnostic fluid in infants, toddlers, youth and adults. However, despite its diagnostic potential, saliva has not yet been established as an analytical tool due to insufficient information regarding salivary biochemical composition and its correlation with plasma levels. Salivary Na, K, total protein, IgA and amylase activity has been shown to increase linearly with age. For example, salivary amylase activity has been shown to be variable and significantly different between infants and toddlers[11]. However, in healthy adults (mean age 22 years), no significant differences were observed in salivary concentrations of glucose, inorganic phosphate, total protein, Mg2+, Cl- and Ca2+ between men and women participants[12]. Interestingly, recent studies demonstrate the diagnostic utility of saliva with implications for cardiovascular disease, systemic and local inflammation, hepatic damage and insulin resistance[8,13,14].

Currently, saliva testing is used in areas of toxicology, endocrinology, infectious diseases, and forensics, with established diagnostic tests available for alcohol detection, HIV infections, hormonal analyses, and drug testing[15,16]. Several studies have demonstrated the use of saliva for detection of antibodies against HIV-1 and HIV-2 under non-laboratory settings[17,18]. The United States Food and Drug Administration (FDA) has recently approved OraQuick, the first over-the-counter, in-home self-testing HIV kit, which uses an oral sample for rapid detection of antibodies against HIV[19]. The assessment of hormones in saliva has been widely studied for routine clinical use[20-22]. The FDA has recently approved the use of enzyme immunoassay technique for *in vitro* diagnostic assay of salivary cortisol for adrenal cortical function and screening for Cushing’s and Addison’s disease[23]. In this review, we explore the potential of using saliva as a non-invasive diagnostic tool for the measurement of biomarkers of insulin-resistance and inflammation.

**GLUCOSE IN SALIVA**

Salivary glucose has been shown to significantly correlate (r = 0.5216, *P* < 0.05) with serum glucose in healthy subjects (*n* = 15). In individuals with newly diagnosed type 2 diabetes (n = 106), salivary glucose demonstrated strong correlation with serum glucose (r = 0.7686, *P* < 0.01) and serum HbA1c (r = 0.5662, *P* < 0.01). Type 2 diabetic patients had significantly higher (*P* < 0.01) mean salivary glucose values (4.22 ± 3.59 mg/mL) compared to healthy controls (1.23 ± 0.52 mg/mL)[24]. Pendyala *et al*[25] have also evaluated serum and salivary glucose in diabetic (men = 26, women = 14) and non-diabetic (men = 28, women = 12) individuals[25]. These authors observed significant correlation between fasting salivary and plasma glucose in both diabetic (r = 0.40) and non-diabetic (r = 0.58) groups. Further, they reported a significant difference in fasting salivary glucose (*P* < 0.001) between diabetic (10.93 ± 1.93 mg/mL) and non-diabetic controls (6.08 ± 1.16 mg/mL). Further, a recent systematic review reported a meaningful increase in salivary glucose concentration in type 2 diabetes that was associated with HbA1c values, suggesting that salivary glucose levels may be a potential biomarker for type 2 DM[26]. Ongoing research is focused on the development of nanotechnology-based biochip sensors for salivary glucose measurements. Such a novel biochemical sensor that provides a compact, high-throughput device for real-time glucose measurements may have implications in point-of-care clinical settings[27].

**INSULIN IN SALIVA**

Salivary insulin, assayed in normal and type 1 diabetic subjects by Pasic and Pickup demonstrated significant correlation between mean serum insulin and salivary insulin (r = 0.81, *P* < 0.01 in non-diabetics and r = 0.91, *P* < 0.001 in type 1 diabetics)[28]. However, because several individual profiles showed marked discrepancies between the timing and magnitude of insulin changes, these authors did not recommend salivary insulin concentrations as a reliable index of insulinemia. More recently, studies by Fabre *et al*[29] demonstrated that salivary insulin concentrations were approximately 10 times lower than serum insulin concentrations[29]. These authors showed a significant correlation ( r = 0.92, *P* < 0.001) between salivary and serum insulin concentrations in 130 boys and 147 girls, aged 6-14 years, suggesting that salivary insulin measurements may be a feasible approach, but suggest the need for additional studies to validate these findings. However, there were no reports that assessed surrogate measures of insulin resistance, including the Homeostasis Assessment Model-estimated insulin resistance (HOMA-IR) or the Quantitative Insulin Sensitivity Check Index (QUICKI)[30,31].

**CORTISOL IN SALIVA**

One of the most widely studied salivary biomarker of stress is the glucocorticoid hormone, cortisol[32,33]. Elevated cortisol production can lead to hypertension, central obesity, insulin resistance and glucose intolerance[34]. In a study of overweight Latino youth (*n* = 211, boys = 119, girls = 92, age between 8 and 13 years) at risk for type 2 diabetes, cortisol was shown to negatively influence insulin sensitivity, and was inversely correlated with fasting glucose (r = 0.23, *P* < 0.01), β-cell function (r = -0.24, *P* < 0.05), and acute insulin response to glucose (r = -0.27, *P* < 0.05)[35]. HPA-axis dysfunction has been associated with various psychological and pathophysiological conditions, and hyperactivity of HPA axis has been observed in individuals with type 2 diabetes[36,37].

Saliva contains free, biologically active cortisol as opposed to total cortisol present in serum or plasma. Further, the concentration of cortisol in saliva is independent of the salivary flow rate and is strongly correlated with circulating cortisol concentrations[33,36]. Cortisol follows a diurnal pattern and any disruption in the rhythm would also be indicative of an HPA dysfunction. The average salivary cortisol concentrations in healthy subjects were reported to be higher in the morning (0.20-1.41 µg/mL) compared to afternoon values (0.04-0.41 µg/mL)[33]. Björntorp *et al*[36] have reported the use of salivary cortisol measurements to monitor the activity of HPA axis. In their study, circulatory perturbations in cortisol expression, which are indicative of increased risk of endocrine abnormalities, insulin resistance, central obesity, dyslipidemia, hypertension and type 2 diabetes, were reflected in the salivary cortisol levels[36].

Data from the Multi-Ethnic Study of Atherosclerosis (MESA) has demonstrated associations between salivary cortisol and markers of inflammation including interleukin (IL)-6, IL-10 and TNF-α in plasma[38]. In this study, IL-6 was found to be most consistently related to cortisol profiles, and higher IL-6 levels were inversely associated with lower cortisol awakening response. In obese individuals (men, *n* = 91; women, *n* = 103) between the ages 19 to 35 years, significant associations were observed between cortisol levels and body fat distribution[39].

Salivary cortisol concentrations are known to increase within 5 min of increases in plasma cortisol, and are generally well correlated with plasma values[40]. There are several salivary cortisol kits available commercially, which commonly use immunoassay techniques or the more recent liquid chromatography-tandem mass spectrophotometry technique. In clinical settings, salivary cortisol is frequently used in the diagnosis of Cushing’s syndrome with reported sensitivities and specificities of 90%[41,42]. Saiyudthong *et al*[43] have conducted a study to compare salivary cortisol levels in healthy individuals (*n* = 83, aged 18-25 years), measured by ELISA and electrochemiluminescence (ECL). Salivary cortisol showed a positive correlation with serum values (r = 0.84, *P* < 0.001) measured using ECL. Further, there was no significant difference between salivary cortisol measured by ELISA and ECL, suggesting ECL as an alternative detection technique for salivary cortisol measurement[43].

**ADIPOKINES IN SALIVA**

Adipose tissue produces several pro-inflammatory and anti-inflammatory factors, including the adipokines leptin, adiponectin, resistin, and visfatin, as well as cytokines such as TNF-a, IL-6, and chemokines such as monocyte chemoattractant protein-1 (MCP-1). These have been shown to participate in the pathogenesis of insulin resistance, adipogenesis and inflammation[44-48].

Recent studies have shown that resistin, visfatin, and adiponectin concentrations can be measured using saliva (Figure 1)[45,46,49]. Mamali *et al*[45] have examined associations between serum and salivary concentrations of adiponectin, resistin and visfatin in healthy individuals (men, *n* = 17; women, *n* = 33) with a mean age of 34 ± 14 years, BMI 22.4 ± 3.6 and body fat percentage 22.4 ± 8.4. In this study, mean salivary (10.92 ng/mL) and serum (12.27 µg/mL) adiponectin levels were shown to be marginally correlated (r = 0.347, *P* = 0.019). There was a significant positive correlation (r = 0.441, p < 0.01) between salivary (1.69 ng/mL) and serum (7.78 ng/mL) resistin values, and no statistical correlation between salivary (9.51 ng/mL) and serum (21.41 ng/mL) visfatin values[45]. Further, the study reported that the differences were not significant between men and women. Similarly, Toda *et al*[50] have demonstrated significant correlation (*P* < 0.05) between plasma and salivary adiponectin values in healthy female participants (n = 30, age > 43 years)[50]. In this study, the authors have compared plasma adiponectin (11.7 µg/mL) concentrations with salivary adiponection in saliva samples collected directly in a test tube (0.89 ng/mL), and with cotton wads using the Salivette system (0.82 ng/mL). There was a significant correlation (*P* < 0.05) between plasma and test-tube saliva samples, and not with the Salivette samples. Salivary detection of proteins such as adiponectin depends largely on salivary processing methods, and the recovery of proteins from saliva. Thanakun *et al*[51] have demonstrated filtration as an alternative saliva processing technique, to the commonly used centrifugation method. In this study, adiponectin levels, following filtration, were comparable to those after centrifugation[51]. In another study, these authors have demonstrated significant association (r = 0.211, p = 0.018) between salivary and plasma adiponection, using ELISA technique, in both healthy individuals (*n* = 46) and patients with metabolic syndrome (*n* = 82). The authors, however, did not observe significant difference in salivary adiponectin between the 2 study groups[52].

In a second study, Yin *et al*[46] have reported significantly higher salivary resistin concentrations (*P* > 0.05) in individuals with newly diagnosed type 2 diabetes (men, *n* = 18; women, *n* = 20) compared to non-diabetic subjects. Salivary resistin was significantly correlated with serum resistin concentrations at different time points of OGTT, and was not affected by an oral glucose load. Further, there was a positive correlation of serum and salivary resistin concentrations with BMI and HOMA-IR in both control and diabetic groups[46]. The studies together indicate that while assay validation and the method of saliva sample collection can play a key role in biomarker quantification and standardization, saliva has the potential to be further explored as a diagnostic tool for adipokine analyses. More research needs to be directed towards developing saliva processing techniques, which can substantially increase the recovery of proteins. Higher protein yields can positively contribute towards improving outcomes of studies determining correlations between saliva and serum concentrations of adipokines.

**INFLAMMATORY BIOMARKERS IN SALIVA**

Inflammation can be caused by a variety of conditions including oxidative stress, overweight/obesity, improper oral hygiene and nutritional deficiencies[1,13,53]. Chronic low-grade inflammation has been associated with systemic diseases, insulin resistance and development of type 2 diabetes[54,55]. Focusing on the need to establish rapid, non-invasive and easy-to-use strategies for disease diagnosis, there has been growing interest in evaluating the potential of saliva for inflammatory marker profiling.

Studies have indicated that the most commonly explored biomarkers of inflammation include antioxidant status and C-reactive protein (CRP) concentrations[53,56-58]. Spectrophotometric assays quantifying levels of thiobarbituric acid reacting substances (TBARS) are used to evaluate salivary antioxidant status, while CRP concentrations are measured using enzyme-linked immunosorbent assay (ELISA) kits or high-sensitivity immunoturbidimetric assays[53,56-59]. However, these tests lack the sensitivity for detection of CRP in saliva. To address the issue of sensitivity, researchers have developed a “lab-on-the-chip” technique for salivary CRP measurements. This novel technique utilizes a microchip assay system that offers the advantages of increased sensitivity (10 pg/mL of CRP) with lower noise-to-signal ratio. The lab-on-the-chip system captures optical signals generated by chemical and immunological reactions performed on microspheres (280 microns in diameter) implanted in silicon microchip wells[60]. Saliva collection techniques reported in clinical studies include the use of unstimulated passive drool or the filter paper method[59,61]. However, it has been observed that correlations between salivary biomarkers were not strong enough to support one collection method over another[61].

Williamson *et al*[61] have reported the presence of 27 cytokine biomarkers including IL-1β, IL-1ra (receptor agonist), IL-2, IL-4, IL-5, IL6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17, eotaxin, basic fibroblast growth hormone (FGF), growth-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, interferon-inducible protein (IP)-10, monocyte chemotactic protein (MCP)-1, macrophage inflammatory proteins (MIPs)-1α, MIP-1β, platelet-derived growth factors (PDGF)-BB, tumor necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF) in the saliva of healthy adults. These cytokines were measured using a commercially available cytokine multiplex assay kit that combines the use of fluorescent flow cytometry and ELISA technology. These authors observed that out of the 27 cytokines tested, only 3 cytokines including IL-6, IFN-γ and MIP-1β, found in saliva samples collected by passive drool, showed significant correlation (*P* < 0.05) with plasma levels[61].

Recently, a novel clinical approach termed, salivary transcriptome diagnostics, has been evaluated to provide a robust, high-throughput and reproducible tool for salivary biomarker detection. Using microarray analysis and quantitative polymerase chain reaction (qPCR), this method has demonstrated high sensitivity (91%) and specificity (91%) for inflammatory biomarkers including IL-8 and IL-1β[62]. Another emerging technique called the oral fluid nanosensor test (OFNASET), offers a rapid and simultaneous detection of multiple salivary proteins, including IL-8 and IL-1β, for point-of-care disease screening and detection. OFNASET involves the use of advanced electrochemical-based molecular analysis platforms including self-assembled monolayers, bionanotechnology, cyclic enzymatic amplification, microfluids, hybridization-based detection, and molecular purification[63].

A recent study in healthy adolescent girls (11-17 years), observed that cytokines including GM-CSF, IL-1β, IL-2, IL-6, IL-8, IL-12p70, TNFα, adiponectin, and cotinine were detectable in saliva. However, the cytokine concentrations, except IL-8 and IL-1β, were lower than serum values and variable at baseline. Further, there were no serum-saliva associations in the levels of cytokines tested[64]. It has been suggested that lack of correlation between salivary and plasma cytokine biomarkers may be due to the impact of oral environment, and the influence of local immunity. It has also been indicated that the variability in cytokine levels may be due to distinct diurnal patterns, reflecting the time of saliva collection[65].

Salivary concentrations of TNF-α and IL-6 have been shown to be elevated in individuals with type 2 diabetes and periodontal disease (*n* = 20, mean age = 57 ± 4 years), compared to healthy subjects (*n* = 21) with periodontal disease[66]. In this study, salivary TNF-α and IL-6 were assayed with ELISA-sandwich technique using commercially available immunoassay kits. In type 2 diabetic patients with periodontal disease, both salivary and serum TNF-α and IL-6 concentrations were significantly higher compared to healthy individuals with periodontal disease. Further, there was a significant correlation (r = 0.500, *P* = 0.057) between salivary and serum IL-6 concentrations, and between salivary IL-6 and parameters including age, BMI, blood glucose and HbA1c. Salivary TNF-α also showed a significant positive correlation (r = 0.674, *P* = 0.0006) with serum concentrations in diabetics with periodontal disease. However, salivary TNF-α was not correlated with age, BMI, blood glucose and HbA1c.

In overweight and obese children (mean age 14.5 years), BMI adjusted for age and gender was shown to be significantly associated with reduced flow rate of stimulated whole saliva (1.2 mL/min), compared to the salivary flow rate (2.0 mL/min) in normal-weight children. This suggested that childhood obesity may cause stimulated whole saliva flow rate to fall below the median value of 1.5 mL/min, which can negatively impact oral health in children[67]. Further, overweight and obese children, between 7 and 10 years of age, have demonstrated a significant decrease in salivary concentrations of phosphate (*P* < 0.001) and peroxidase activity (*P* < 0.001), and an increase in free sialic acid (*P* = 0.004) and protein (*P* = 0.003) levels compared to normal weight control group suggesting the influence of BMI on stimulated whole saliva composition[68].

**C-REACTIVE PROTEIN IN SALIVA**

C-reactive protein (CRP) is a sensitive marker of systemic inflammation and an independent risk factor for cardiovascular diseases in both adults and children[69,70]. In a study of 170 black South African children (age 10 ± 2 years; boys, *n* = 70; girls, *n* = 100) salivary CRP concentrations, determined using a commercially available CRP ELISA kit, showed that obese children (*n* = 53, boys = 24, girls = 29, mean BMI = 26.2 ± 5 kg/m2) had significantly higher (*P* < 0.05) salivary CRP concentration (7.31 ± 0.93 pg/mL) compared to normal-weight control group (6.77 ± 0.92 pg/mL)[57]. Further, obese children were also shown to have significantly higher (*P* < 0.05) salivary CRP secretion rate (7.25 ± 0.99 pg/min) compared to normal weight children (6.68 ± 0.98 pg/min).

In healthy individuals (men, *n* = 13; women, *n* = 12) between 20 to 35 years age, salivary CRP concentrations have been shown to be in the range of 35-217 pg/mL for saliva collected using the passive drool method. Use of acid-stimulation for saliva collection have shown lower salivary CRP concentrations (38-171 pg/mL) compared to saliva collected using mechanical stimulation (32-213 pg/mL)[71]. In this study, a commercially available ELISA kit (AlphaLISA, PerkinElmer, MA, United States) was used for quantification of salivary CRP. Another study has reported salivary CRP concentrations in the range of 118 to 24,156 pg/mL in healthy participants (*n* = 61) between 20 and 54 years of age[72]. In this study, saliva samples were collected using the unstimulated passive drool method and salivary CRP was measured with a commercial ELISA kit (Salimetrics LLC, Carlsbad, CA). The observed differences in salivary CRP range among healthy individuals may be explained by differences in pre-processing techniques, and the use of different assay kits. Further, these authors have shown that salivary and serum CRP concentrations were correlated (r = 0.72). Further, it was shown that salivary CRP concentrations could predict serum CRP concentrations with 89% accuracy at higher mean serum values.

However, Qvarnstrom *et al*[58] have reported that salivary CRP was not significantly associated with metabolic syndrome in patients with or without coronary artery disease[58]. In this study, out of 250 participants with coronary artery disease, 81 had metabolic syndrome, and salivary lysozyme was shown to be significantly associated with metabolic syndrome (*P* = 0.02), independent of CRP concentrations. While comparing saliva and plasma CRP concentrations, Dillon *et al*[59] have reported that CRP concentrations in saliva of healthy adults (*n* = 69) ranged between 0.05 to 64.3 µg/L, which were significantly lower compared to plasma CRP concentrations (0.14 to 31.1 mg/L). Further, regression analysis showed no correlation between CRP concentrations in saliva and plasma (*R*2 = 0.001)[59]. In this study, unstimulated whole saliva samples were obtained by the passive drool method and salivary CRP concentrations were measured using a commercial kit (Salimetrics). Interestingly, salivary CRP concentrations have been shown to be positively correlated with serum concentrations in patients (*n* = 56) with acute myocardial infarction[73]. In this study, CRP showed the highest median concentration, for diseased over control subjects, in both serum (4.29) and saliva (72.25) followed by MMP-9, IL-1β, sICAM-1, MPO, adiponectin and MCP-1. Receiver-operating characteristic curve analysis showed that CRP had a significantly higher area under the curve for saliva (AUC = 0.78, *P* < 0.05). The current developments in identifying and standardizing potential inflammatory biomarkers in saliva suggest that substantial research is required to standardize and validate the use of clinically relevant biomarkers in disease diagnosis[74].

**ANTIOXIDANT STATUS IN SALIVA**

Oxidative stress is another major cause of obesity-induced inflammation resulting from increased production of free radicals and/or low antioxidant status. Oral inflammation is associated with elevated systemic inflammation, and has been linked with increased risk of insulin resistance and diabetes[24]. In a study by Al-Rawi[56], the oxidative status of type 2 diabetic patients was evaluated by measuring salivary and serum levels of malondialdehyde (MDA), uric acid (UA), superoxide dismutase (SOD) and reduced glutathione (GSH). Salivary concentrations of MDA were lower (between 0.29-0.98 µmol/L) compared to serum MDA values (0.85-4.31 µmol/L) in all the study groups. However, salivary MDA was significantly higher in participants with type 2 diabetes compared to control subjects. Further, UA and GSH concentrations were significantly elevated (*P* < 0.001) in saliva of diabetic patients, while salivary GSH showed no significant change compared to the control group[56].

Type 2 diabetes has also been associated with decreased total antioxidant capacity (TAC) evaluated by spectrophotometric measurement of TBARS[25]. In this study, salivary TAC content (1.24 ± 0.18) was significantly lower in diabetes group (*n* = 30, 13 men and 17 women) compared to healthy controls (*n* = 30, 4.6 ± 0.31). Further, there was a significant decrease (*P* < 0.01) in the salivary flow rates in subjects with diabetes (0.38 ± 0.16) compared to the healthy individuals (0.65 ± 0.10). A recent study has demonstrated increased concentrations of pro-inflammatory cytokines in unstimulated whole saliva samples collected from pregnant women with diabetes (*n* = 63). The findings of this study suggested that changes in saliva properties were more pronounced in long-term cases of diabetes and partly correlated with HbA1c[75].

**SALIVA RESEARCH: EMERGING STUDIES**

Currently, there has been an increasing focus on proteomic analysis of saliva. Research is directed to identify and catalog human salivary proteins. Recently, a NIDCR-supported research consortium has compiled an extensive list of whole saliva proteins, using mass spectrophotometric techniques. This research group has identified 597 salivary proteins that are also found in the plasma[76].

Studies are being conducted to develop sensitive and reliable saliva-based diagnostic assays with the potential to be used in a clinical setting. Researchers have evaluated the use of a Luciferase Immunoprecipitation System (LIPS) for detection of autoantibodies in salivary and lacrimal gland secretions of patients with Sjogren’s Syndrome (SjS)[27]. This assay has been reported to detect autoantibodies in 67% of SjS patients with 100% specificity suggesting its potential use as an alternative to serum.

Interestingly, approximately 50 microRNAs have been identified in whole saliva, which currently are being studied for their potential to serve as biomarkers of oral cancer[77]. Scientists have also developed a surface immobilized optical protein sensor to detect IL-8 with implications for use in cancer detection. To overcome the challenge of detecting low concentrations of biomarkers in saliva, the authors propose use of confocal optical sensors[78].

**CONCLUSION**

While low-grade inflammation, a hallmark of obesity, may be a pivotal mechanism linking obesity to its numerous systemic complications, these require invasive procedures, such as blood drawing. Recently, interest in the use of saliva as a diagnostic fluid has increased exponentially because of its non-invasive nature and potential to be used in population-based screening programs, confirmatory diagnosis, risk stratification, prognosis determination, and therapy response. Salivary cortisol is becoming widely used as a screening test for the diagnosis of hypercorticolism and as a biomarker of psychological stress. Current literature for diagnostic potential of salivary biomarkers suggests that salivary CRP, TNF-α, IL-6, and IFN-γ are elevated in overweight/obesity and inflammatory conditions in children, and adults. These salivary biomarkers demonstrate moderate-to-strong correlation with serum biomarkers, in healthy as well as obese and diabetic individuals. Salivary markers of antioxidant status, including malondialdehyde and uric acid, show promise but will need to be explored further. While some studies show that salivary resistin and adiponectin concentrations are significantly correlated with serum values, and are known to be been elevated in obesity and diabetes, additional studies are needed to characterize such biomolecules in saliva and their relevance to inflammatory, metabolic, and cardiovascular conditions.

In conclusion, while saliva has the potential to become a premier diagnostic sample, substantial future research is required to standardize saliva collection techniques, validate salivary biomarkers of inflammation and insulin-resistance, across various life-stages and conditions, and establish reference ranges, before it can be used as a diagnostic fluid for cardiometabolic risk assessment.

**REFERENCES**

1 **de Almeida Pdel V**, Grégio AM, Machado MA, de Lima AA, Azevedo LR. Saliva composition and functions: a comprehensive review. *J Contemp Dent Pract* 2008; **9**: 72-80 [PMID: 18335122]

2 **Mandel ID**. The functions of saliva. *J Dent Res* 1987; **66** Spec No: 623-627 [PMID: 3497964]

3 **Inoue H**, Ono K, Masuda W, Inagaki T, Yokota M, Inenaga K. Rheological properties of human saliva and salivary mucins. *J Oral Biosci* 2008; **50:** 134-141 [DOI: 10.1016/S1349-0079(08)80027-8]

4 **Baum BJ**, Yates JR, Srivastava S, Wong DT, Melvin JE. Scientific frontiers: emerging technologies for salivary diagnostics. *Adv Dent Res* 2011; **23**: 360-368 [PMID: 21917746 DOI: 10.1177/0022034511420433]

5 **Stokes JR**, Davies GA. Viscoelasticity of human whole saliva collected after acid and mechanical stimulation. *Biorheology* 2007; **44**: 141-160 [PMID: 17851164]

6 **van der Reijden WA**, Veerman EC, Amerongen AV. Shear rate dependent viscoelastic behavior of human glandular salivas. *Biorheology* 1993; **30**: 141-152 [PMID: 8400152]

7 **Rhoades R**, Bell DR. Medical Physiology: Principles of Clinical Medicine. Chapter 26: Gastrointestinal Secretion, Digestion, and Absorption. 4th ed. Lippincott Williams & Wilkins, 2013

8 **Pfaffe T**, Cooper-White J, Beyerlein P, Kostner K, Punyadeera C. Diagnostic potential of saliva: current state and future applications. *Clin Chem* 2011; **57**: 675-687 [PMID: 21383043 DOI: 10.1373/clinchem.2010.153767]

9 **Kaufman E**, Lamster IB. The diagnostic applications of saliva--a review. *Crit Rev Oral Biol Med* 2002; **13**: 197-212 [PMID: 12097361]

10 **Fenoll-Palomares C**, Muñoz Montagud JV, Sanchiz V, Herreros B, Hernández V, Mínguez M, Benages A. Unstimulated salivary flow rate, pH and buffer capacity of saliva in healthy volunteers. *Rev Esp Enferm Dig* 2004; **96**: 773-783 [PMID: 15584851]

11 **Ben-Aryeh H**, Fisher M, Szargel R, Laufer D. Composition of whole unstimulated saliva of healthy children: changes with age. *Arch Oral Biol* 1990; **35**: 929-931 [PMID: 1704211]

12 **Agha-Hosseini F**, Dizgah IM, Amirkhani S. The composition of unstimulated whole saliva of healthy dental students. *J Contemp Dent Pract* 2006; **7**: 104-111 [PMID: 16685301]

13 **Yoon AJ**, Cheng B, Philipone E, Turner R, Lamster IB. Inflammatory biomarkers in saliva: assessing the strength of association of diabetes mellitus and periodontal status with the oral inflammatory burden. *J Clin Periodontol* 2012; **39**: 434-440 [PMID: 22420648 DOI: 10.1111/j.1600-051X.2012.01866.x]

14 **Shivashankara AR,** Johnny C, Malathi M, Arun Kumar K, Avinash SS, Thomas T. A correlative study on the aminotransferses and gamma glutamyl transferase in the saliva and serum of chronic alcoholics before and after alcohol deaddiction. *J Clin Diagn Res* 2011; **5**: 512-515

15 **National Institute of Health Fact Sheet.** Salivary Diagnostics 2014. [accessed 2014 May 15]. Available from: http: //report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=65

16 **Wylie FM**, Torrance H, Anderson RA, Oliver JS. Drugs in oral fluid Part I. Validation of an analytical procedure for licit and illicit drugs in oral fluid. *Forensic Sci Int* 2005; **150**: 191-198 [PMID: 15944059 DOI: 10.1016/j.forsciint.2005.02.024]

17 **Mortimer PP**, Parry JV. Detection of antibody to HIV in saliva: a brief review. *Clin Diagn Virol* 1994; **2**: 231-243 [PMID: 15566769]

18 **Schramm W**, Angulo GB, Torres PC, Burgess-Cassler A. A simple saliva-based test for detecting antibodies to human immunodeficiency virus. *Clin Diagn Lab Immunol* 1999; **6**: 577-580 [PMID: 10391866]

19 **US Food and Drug Administration.** First rapid home-use HIV kit approved for self-testing 2012. Available from: http: //www.fda.gov/forconsumers/consumerupdates/ucm310545.htm

20 **Gröschl M**. Current status of salivary hormone analysis. *Clin Chem* 2008; **54**: 1759-1769 [PMID: 18757583 DOI: 10.1373/clinchem.2008.108910]

21 **Vining RF**, McGinley RA. The measurement of hormones in saliva: possibilities and pitfalls. *J Steroid Biochem* 1987; **27**: 81-94 [PMID: 3320544 DOI: 10.1016/0022-4731(87)90297-4]

22 **Riad-Fahmy D**, Read GF, Walker RF, Griffiths K. Steroids in saliva for assessing endocrine function. *Endocr Rev* 1982; **3**: 367-395 [PMID: 6217969 DOI: 10.1210/edrv-3-4-367]

23 **US Food and Drug Administration.** Immunoassay for the in vitro quantitative determination of cortisol in saliva. 2003. Available from: http: //www.accessdata.fda.gov/cdrh\_docs/pdf3/k031348.pdf

24 **Mealey BL**, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. *Curr Opin Endocrinol Diabetes Obes* 2008; **15**: 135-141 [PMID: 18316948 DOI: 10.1097/MED.0b013e3282f824b7]

25 **Pendyala G**, Thomas B, Joshi SR. Evaluation of Total Antioxidant Capacity of Saliva in Type 2 Diabetic Patients with and without Periodontal Disease: A Case-Control Study. *N Am J Med Sci* 2013; **5**: 51-57 [PMID: 23378957 DOI: 10.4103/1947-2714.106208]

26 **Mascarenhas P**, Fatela B, Barahona I. Effect of diabetes mellitus type 2 on salivary glucose--a systematic review and meta-analysis of observational studies. *PLoS One* 2014; **9**: e101706 [PMID: 25025218 DOI: 10.1371/journal.pone.0101706]

27 **Ching KH**, Burbelo PD, Gonzalez-Begne M, Roberts ME, Coca A, Sanz I, Iadarola MJ. Salivary anti-Ro60 and anti-Ro52 antibody profiles to diagnose Sjogren's Syndrome. *J Dent Res* 2011; **90**: 445-449 [PMID: 21212317 DOI: 10.1177/0022034510390811]

28 **Pasic J**, Pickup JC. Salivary insulin in normal and type I diabetic subjects. *Diabetes Care* 1988; **11**: 489-494 [PMID: 3042316]

29 **Fabre B**, Maccallini G, Oneto A, Gonzalez D, Hirschler V, Aranda C, Berg G. Measurement of fasting salivary insulin and its relationship with serum insulin in children. *Endocr Connect* 2012; **1**: 58-61 [PMID: 23781305 DOI: 10.1530/EC-12-0024]

30 **Matthews DR**, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; **28**: 412-419 [PMID: 3899825]

31 **Katz A**, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000; **85**: 2402-2410 [PMID: 10902785]

32 **Cabral DM**, Antonini SR, Custódio RJ, Martinelli CE, da Silva CA. Measurement of salivary cortisol as a marker of stress in newborns in a neonatal intensive care unit. *Horm Res Paediatr* 2013; **79**: 373-378 [PMID: 23796826 DOI: 10.1159/000351942]

33 **Bozovic D**, Racic M, Ivkovic N. Salivary cortisol levels as a biological marker of stress reaction. *Med Arch* 2013; **67**: 374-377 [PMID: 24601177]

34 **Andrews RC**, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. *Clin Sci (Lond)* 1999; **96**: 513-523 [PMID: 10209084]

35 **Adam TC**, Hasson RE, Ventura EE, Toledo-Corral C, Le KA, Mahurkar S, Lane CJ, Weigensberg MJ, Goran MI. Cortisol is negatively associated with insulin sensitivity in overweight Latino youth. *J Clin Endocrinol Metab* 2010; **95**: 4729-4735 [PMID: 20660036 DOI: 10.1210/jc.2010-0322]

36 **Björntorp P**, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. *Diabet Med* 1999; **16**: 373-383 [PMID: 10342336]

37 **Jessop DS**, Turner-Cobb JM. Measurement and meaning of salivary cortisol: a focus on health and disease in children. *Stress* 2008; **11**: 1-14 [PMID: 17853059 DOI: 10.1080/10253890701365527]

38 **DeSantis AS**, DiezRoux AV, Hajat A, Aiello AE, Golden SH, Jenny NS, Seeman TE, Shea S. Associations of salivary cortisol levels with inflammatory markers: the Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology* 2012; **37**: 1009-1018 [PMID: 22178583 DOI: 10.1016/j.psyneuen.2011.11.009]

39 **Rutters F**, Nieuwenhuizen AG, Lemmens SG, Born JM, Westerterp-Plantenga MS. Hypothalamic-pituitary-adrenal (HPA) axis functioning in relation to body fat distribution. *Clin Endocrinol (Oxf)* 2010; **72**: 738-743 [PMID: 19769618 DOI: 10.1111/j.1365-2265.2009.03712.x]

40 **Inder WJ**, Dimeski G, Russell A. The Hypothalamic-Pituitary-Adrenal Axis, Obesity, and Chronic Stress Exposure: Sleep and the HPA Axis in Obesity. *Curr Obes Rep* 2012; **1**: 208-215 [PMID: 23162786 DOI: 10.1007/s13679-012-0028-5]

41 **Inder WJ**, Dimeski G, Russell A. Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications. *Clin Endocrinol (Oxf)* 2012; **77**: 645-651 [PMID: 22812714 DOI: 10.1111/j.1365-2265.2012.04508.x]

42 **Lo MS**, Ng ML, Azmy BS, Khalid BA. Clinical applications of salivary cortisol measurements. *Singapore Med J* 1992; **33**: 170-173 [PMID: 1621122]

43 **Saiyudthong S,** Suwannarat P, Trongwongsa T, Srisurapanon S. Comparison between ECL and ELISA for the detection of salivary cortisol and determination of the relationship between cortisol in saliva and serum measured by ECL. *Science Asia* 2010; **36**: 169-171 [DOI: 10.2306/scienceasia1513-1874.2010.36.169]

44 **Guerre-Millo M**. Adiponectin: an update. *Diabetes Metab* 2008; **34**: 12-18 [PMID: 18069030 DOI: 10.1016/j.diabet.2007.08.002]

45 **Mamali I**, Roupas ND, Armeni AK, Theodoropoulou A, Markou KB, Georgopoulos NA. Measurement of salivary resistin, visfatin and adiponectin levels. *Peptides* 2012; **33**: 120-124 [PMID: 22108712 DOI: 10.1016/j.peptides.2011.11.007]

46 **Yin J**, Gao H, Yang J, Xu L, Li M. Measurement of salivary resistin level in patients with type 2 diabetes. *Int J Endocrinol* 2012; **2012**: 359724 [PMID: 22969799 DOI: 10.1155/2012/359724]

47 **Fukuhara A**, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science* 2005; **307**: 426-430 [PMID: 15604363 DOI: 10.1126/science.1097243]

48 **Sommer G**, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M, Fasshauer M. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. *Clin Sci (Lond)* 2008; **115**: 13-23 [PMID: 19016657 DOI: 10.1042/cs20070226]

49 **Toda M**, Tsukinoki R, Morimoto K. Measurement of salivary adiponectin levels. *Acta Diabetol* 2007; **44**: 20-22 [PMID: 17357881 DOI: 10.1007/s00592-007-0236-8]

50 **Toda M**, Morimoto K. Comparison of saliva sampling methods for measurement of salivary adiponectin levels. *Scand J Clin Lab Invest* 2008; **68**: 823-825 [PMID: 18618368]

51 **Thanakun S**, Watanabe H, Thaweboon S, Izumi Y. An effective technique for the processing of saliva for the analysis of leptin and adiponectin. *Peptides* 2013; **47**: 60-65 [PMID: 23851006 DOI: 10.1016/j.peptides.2013.06.010]

52 **Thanakun S**, Watanabe H, Thaweboon S, Izumi Y. Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome. *Diabetol Metab Syndr* 2014; **6**: 19 [PMID: 24528653 DOI: 10.1186/1758-5996-6-19]

53 **Vlková B**, Stanko P, Minárik G, Tóthová L, Szemes T, Baňasová L, Novotňáková D, Hodosy J, Celec P. Salivary markers of oxidative stress in patients with oral premalignant lesions. *Arch Oral Biol* 2012; **57**: 1651-1656 [PMID: 23092610]

54 **Gurenlian JR**. Inflammation: the relationship between oral health and systemic disease. *Dent Assist* 2009; **78**: 8-10, 12-4, 38-40; quiz 41-3 [PMID: 19413061]

55 **de Luca C**, Olefsky JM. Inflammation and insulin resistance. *FEBS Lett* 2008; **582**: 97-105 [PMID: 18053812]

56 **Al-Rawi NH**. Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics. *Diab Vasc Dis Res* 2011; **8**: 22-28 [PMID: 21262867 DOI: 10.1177/1479164110390243]

57 **Naidoo T**, Konkol K, Biccard B, Dudose K, McKune AJ. Elevated salivary C-reactive protein predicted by low cardio-respiratory fitness and being overweight in African children. *Cardiovasc J Afr* 2012; **23**: 501-506 [PMID: 23108518 DOI: 10.5830/cvja-2012-058]

58 **Qvarnstrom M**, Janket SJ, Jones JA, Jethwani K, Nuutinen P, Garcia RI, Baird AE, Van Dyke TE, Meurman JH. Association of salivary lysozyme and C-reactive protein with metabolic syndrome. *J Clin Periodontol* 2010; **37**: 805-811 [PMID: 20666873 DOI: 10.1111/j.1600-051X.2010.01605.x]

59 **Dillon MC**, Opris DC, Kopanczyk R, Lickliter J, Cornwell HN, Bridges EG, Nazar AM, Bridges KG. Detection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levels. *Biomark Insights* 2010; **5**: 57-61 [PMID: 20703322]

60 **Christodoulides N**, Mohanty S, Miller CS, Langub MC, Floriano PN, Dharshan P, Ali MF, Bernard B, Romanovicz D, Anslyn E, Fox PC, McDevitt JT. Application of microchip assay system for the measurement of C-reactive protein in human saliva. *Lab Chip* 2005; **5**: 261-269 [PMID: 15726202]

61 **Williamson S**, Munro C, Pickler R, Grap MJ, Elswick RK. Comparison of biomarkers in blood and saliva in healthy adults. *Nurs Res Pract* 2012; **2012**: 246178 [PMID: 22619709 DOI: 10.1155/2012/246178]

62 **Li Y**, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH, Wong DT. Salivary transcriptome diagnostics for oral cancer detection. *Clin Cancer Res* 2004; **10**: 8442-8450 [PMID: 15623624]

63 **Gau V**, Wong D. Oral fluid nanosensor test (OFNASET) with advanced electrochemical-based molecular analysis platform. *Ann N Y Acad Sci* 2007; **1098**: 401-410 [PMID: 17435145]

64 **Riis JL**, Out D, Dorn LD, Beal SJ, Denson LA, Pabst S, Jaedicke K, Granger DA. Salivary cytokines in healthy adolescent girls: Intercorrelations, stability, and associations with serum cytokines, age, and pubertal stage. *Dev Psychobiol* 2014; **56**: 797-811 [PMID: 23868603 DOI: 10.1002/dev.21149]

65 **Izawa S**, Miki K, Liu X, Ogawa N. The diurnal patterns of salivary interleukin-6 and C-reactive protein in healthy young adults. *Brain Behav Immun* 2013; **27**: 38-41 [PMID: 22796263 DOI: 10.1016/j.bbi.2012.07.001]

66 Monea A, Gruber R, Elod N, Beresescu G, Moldovn C, Monea M. Saliva and serum levels of TNF-alpha and IL-6 in a sample of Romanian adult subjects with Type 2 diabetes mellitus and periodontal disease. European Scientific Journal 2014; 10: 350-359

67 **Modéer T**, Blomberg CC, Wondimu B, Julihn A, Marcus C. Association between obesity, flow rate of whole saliva, and dental caries in adolescents. *Obesity (Silver Spring)* 2010; **18**: 2367-2373 [PMID: 20339364 DOI: 10.1038/oby.2010.63]

68 **Pannunzio E**, Amancio OM, Vitalle MS, Souza DN, Mendes FM, Nicolau J. Analysis of the stimulated whole saliva in overweight and obese school children. *Rev Assoc Med Bras* 2010; **56**: 32-36 [PMID: 20339783]

69 **Cook DG**, Mendall MA, Whincup PH, Carey IM, Ballam L, Morris JE, Miller GJ, Strachan DP. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. *Atherosclerosis* 2000; **149**: 139-150 [PMID: 10704625 DOI: 10.1016/S0021-9150(99)00312-3]

70 **Ridker PM**, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation* 2003; **107**: 391-397 [PMID: 12551861]

71 **Mohamed R**, Campbell JL, Cooper-White J, Dimeski G, Punyadeera C. The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. *Clin Transl Med* 2012; **1**: 19 [PMID: 23369566 DOI: 10.1186/2001-1326-1-19]

72 **Ouellet-Morin I**, Danese A, Williams B, Arseneault L. Validation of a high-sensitivity assay for C-reactive protein in human saliva. *Brain Behav Immun* 2011; **25**: 640-646 [PMID: 21236331 DOI: 10.1016/j.bbi.2010.12.020]

73 **Floriano PN**, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, Kinane DF, Novak MJ, Steinhubl S, Acosta S, Mohanty S, Dharshan P, Yeh CK, Redding S, Furmaga W, McDevitt JT. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. *Clin Chem* 2009; **55**: 1530-1538 [PMID: 19556448 DOI: 10.1373/clinchem.2008.117713]

74 **Miller CS**, Foley JD, Bailey AL, Campell CL, Humphries RL, Christodoulides N, Floriano PN, Simmons G, Bhagwandin B, Jacobson JW, Redding SW, Ebersole JL, McDevitt JT. Current developments in salivary diagnostics. *Biomark Med* 2010; **4**: 171-189 [PMID: 20387312]

75 **Surdacka A**, Ciężka E, Pioruńska-Stolzmann M, Wender-Ożegowska E, Korybalska K, Kawka E, Kaczmarek E, Witowski J. Relation of salivary antioxidant status and cytokine levels to clinical parameters of oral health in pregnant women with diabetes. *Arch Oral Biol* 2011; **56**: 428-436 [PMID: 21145038 DOI: 10.1016/j.archoralbio.2010.11.005]

76 [**Yan W**](http://www.ncbi.nlm.nih.gov/pubmed?term=Yan%20W%5BAuthor%5D&cauthor=true&cauthor_uid=19898684)**,** [Apweiler R](http://www.ncbi.nlm.nih.gov/pubmed?term=Apweiler%20R%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Balgley BM](http://www.ncbi.nlm.nih.gov/pubmed?term=Balgley%20BM%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Boontheung P](http://www.ncbi.nlm.nih.gov/pubmed?term=Boontheung%20P%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Bundy JL](http://www.ncbi.nlm.nih.gov/pubmed?term=Bundy%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Cargile BJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Cargile%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Cole S](http://www.ncbi.nlm.nih.gov/pubmed?term=Cole%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Fang X](http://www.ncbi.nlm.nih.gov/pubmed?term=Fang%20X%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Gonzalez-Begne M](http://www.ncbi.nlm.nih.gov/pubmed?term=Gonzalez-Begne%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Griffin TJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Griffin%20TJ%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Hagen F](http://www.ncbi.nlm.nih.gov/pubmed?term=Hagen%20F%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Hu S](http://www.ncbi.nlm.nih.gov/pubmed?term=Hu%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Wolinsky LE](http://www.ncbi.nlm.nih.gov/pubmed?term=Wolinsky%20LE%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Lee CS](http://www.ncbi.nlm.nih.gov/pubmed?term=Lee%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=19898684),[Malamud D](http://www.ncbi.nlm.nih.gov/pubmed?term=Malamud%20D%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Melvin JE](http://www.ncbi.nlm.nih.gov/pubmed?term=Melvin%20JE%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Menon R](http://www.ncbi.nlm.nih.gov/pubmed?term=Menon%20R%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Mueller M](http://www.ncbi.nlm.nih.gov/pubmed?term=Mueller%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Qiao R](http://www.ncbi.nlm.nih.gov/pubmed?term=Qiao%20R%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Rhodus NL](http://www.ncbi.nlm.nih.gov/pubmed?term=Rhodus%20NL%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Sevinsky JR](http://www.ncbi.nlm.nih.gov/pubmed?term=Sevinsky%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [States D](http://www.ncbi.nlm.nih.gov/pubmed?term=States%20D%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Stephenson JL](http://www.ncbi.nlm.nih.gov/pubmed?term=Stephenson%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Than S](http://www.ncbi.nlm.nih.gov/pubmed?term=Than%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Yates JR](http://www.ncbi.nlm.nih.gov/pubmed?term=Yates%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Yu W](http://www.ncbi.nlm.nih.gov/pubmed?term=Yu%20W%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Xie H](http://www.ncbi.nlm.nih.gov/pubmed?term=Xie%20H%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Xie Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Xie%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Omenn GS](http://www.ncbi.nlm.nih.gov/pubmed?term=Omenn%20GS%5BAuthor%5D&cauthor=true&cauthor_uid=19898684),[Loo JA](http://www.ncbi.nlm.nih.gov/pubmed?term=Loo%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=19898684), [Wong DT](http://www.ncbi.nlm.nih.gov/pubmed?term=Wong%20DT%5BAuthor%5D&cauthor=true&cauthor_uid=19898684). Systematic comparison of the human saliva and plasma proteomes. *Proteomics Clin Appl* 2009; **3**: 116-134 [PMID: 19898684 DOI: 10.1002/prca.200800140]

77 **Park NJ**, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. *Clin Cancer Res* 2009; **15**: 5473-5477 [PMID: 19706812 DOI: 10.1158/1078-0432.ccr-09-0736]

78 **Tan W**, Sabet L, Li Y, Yu T, Klokkevold PR, Wong DT, Ho CM. Optical protein sensor for detecting cancer markers in saliva. *Biosens Bioelectron* 2008; **24**: 266-271 [PMID: 18479906 DOI: 10.1016/j.bios.2008.03.037]

**P-Reviewer:** Chen YK, Gokul S **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Figure 1 Salivary biomarkers of inflammation and insulin resistance.** TAC: Total antioxidant capacity; MDA: malondialdehyde; UA: Uric acid; SOD: Superoxide dismutase; GSH: Glutathione reductase; CRP: C-reactive protein; TNF-α: Tumor necrosis factor-alpha; IL-6: Interleukin-6; IFN-γ: Interferon gamma; MIP-1b: Macrophage inflammatory protein-1 beta.****